Decoy Therapeutics stockholders elect Patricia Gauthier as Class II director

The July 14 annual meeting also re-elected Rick Pierce and Jon Lieber, as the biotech company advances its Designable Multi-Antivirals programs toward the clinic.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.